Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients

Climacteric

Volumn 11, Issue 4, 2008, Pages 287-295

  Iizuka, Takahiro ^a   Matsukawa, Mitsuhiro ^a  

^a Kawasaki Hospital   (Japan)

Author keywords

BAP; Long term bisphosphonate therapy; Osteoporosis; Suppression; u NTx

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID;

AGED; ARTICLE; BONE TURNOVER; BRAIN INFARCTION; CONTROLLED STUDY; DEMENTIA; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; JAPANESE; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MORNING DOSAGE; OSSIFICATION; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT DURATION; URINALYSIS;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; ALKALINE PHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; COLLAGEN TYPE I; ETIDRONIC ACID; FEMALE; HUMANS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDES; PROSPECTIVE STUDIES;

EID: 47749121016     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130801959590     Document Type: Article

References (26)

1. Hosking D, Adami S, Felsenberg D, Andia JC. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized, placebo-controlled study. Curr Med Res Opin 2003;19:383-94
2. Susan L, Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85:3537-40
3. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-15
4. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-8
5. Fogelman I, Ribot C, Smith R, Ethgen D. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:1895-900
6. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52
7. Allen MR, Iwata K, Sato M, Burr DB. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 2006;39:1130-5
8. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999;42:1246-54
9. Chesnut CH, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37
10. Estell R, Barton I, Hannon R. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6
11. Garnero P, Sornay-Rendu E, Duboeuf F. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: OFELY Study. J Bone Miner Res 1999;14:1614-21
12. Delmas PD, Eastell R, Garnero P, Seibel MJ. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000;6:s2-17
13. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700
14. Briot K, Tremollieres F, Thomas T, Roux C. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 2007;74:24-31
15. Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007;74:39-47
16. Miller PD. Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. Expert Opin Pharmacother 2003;4:2253-8
17. Reginster JY. Adherence and persistence: impact on outcomes and health care resources. Bone 2006;38:S18-21
18. Reid DM. Once-monthly dosing: an effective step forward. Bone 2006;38:S18-22
19. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006;38:S2-6
20. Odvina CV, Zerwekh JE, Rao S, Maalouf N, Gottschalk FA, Pak CY. Severe suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endorinol Metab 2005;90:1294-301
21. Karsdal MA, Qvist P, Chritiansen C, Tanko L. Optimising antiresorptive therapies in postmenopausal women. Drugs 2006;66:1909-18
22. Garnero P, Darte C, Delmas PD. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 1999;24:603-9
23. Alvarez L, Peris P, Guanabens N, et al. Long-term biochemical response after bisphosphonates therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Rheumatology 2004;43:869-74
24. Delmas PD, Hardy P, Garnero P, Dain MP. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000;26:553-60
25. Cao Yongping, Mori S, Mashiba T, Westmore MS. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002;17:2237-46
26. Silverman SL, Watts PD, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study. Osteoporosis Int 2007;18:25-34